Literature DB >> 15820166

Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction.

Kenneth A Schwartz1, Dianne E Schwartz, Khalid Ghosheh, Mathew J Reeves, Kimberly Barber, Anthony DeFranco.   

Abstract

The hypothesis that aspirin resistance is often due to noncompliance was investigated. One hundred ninety patients with a history of myocardial infarction were evaluated using arachidonic acid-stimulated light aggregometry at 3 different time points: while receiving their usual daily aspirin, after not receiving aspirin for 7 days, and 2 hours after the observed ingestion of aspirin 325 mg. At the first time point, 17 patients (9%) failed to show aspirin inhibition of platelet aggregation, but 2 hours after observed aspirin ingestion, aspirin inhibition was observed in all but 1 patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15820166     DOI: 10.1016/j.amjcard.2004.12.038

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  33 in total

Review 1.  Old and new molecular mechanisms associated with platelet resistance to antithrombotics.

Authors:  Antonio J López Farré; Juan Tamargo; Petra J Mateos-Cáceres; Luís Azcona; Carlos Macaya
Journal:  Pharm Res       Date:  2010-07-14       Impact factor: 4.200

2.  Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study.

Authors:  Abdalla Awidi; Akram Saleh; Manar Dweik; Baraah Kailani; Mohammed Abu-Fara; Rinad Nabulsi; Abdulbari Bener
Journal:  Heart Vessels       Date:  2010-12-23       Impact factor: 2.037

3.  Aspirin resistance: What is the risk of cardiovascular morbidity?

Authors:  Peter Elwood; Gareth Morgan
Journal:  BMJ       Date:  2008-02-09

4.  Aspirin resistance and diabetes mellitus.

Authors:  R Ajjan; R F Storey; P J Grant
Journal:  Diabetologia       Date:  2008-03       Impact factor: 10.122

5.  Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy.

Authors:  A Anil Timur; Gurunathan Murugesan; Li Zhang; John Barnard; Deepak L Bhatt; Kandice Kottke-Marchant
Journal:  Thromb Res       Date:  2014-04-29       Impact factor: 3.944

6.  Platelet aggregation in intracranial stents may mimic in-stent restenosis.

Authors:  M Mazighi; J P Saint Maurice; D Bresson; Z Szatmary; E Houdart
Journal:  AJNR Am J Neuroradiol       Date:  2009-10-15       Impact factor: 3.825

Review 7.  Obesity and Altered Aspirin Pharmacology.

Authors:  Nicholas B Norgard
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

Review 8.  Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4.

Authors:  Wei C Lau; Paul A Gurbel
Journal:  Pharm Res       Date:  2006-10-24       Impact factor: 4.200

9.  Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.

Authors:  S Prabhakaran; K R Wells; V H Lee; C A Flaherty; D K Lopes
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

Review 10.  Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care.

Authors:  Marc Cohen
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.